8-K: Entera Bio Accelerates Oral Osteoporosis Drug to Phase 3

Entera Bio submitted a streamlined Phase 3 protocol to the FDA for its oral osteoporosis treatment, EB613, anticipating topline data by late 2028, approximately one year earlier than expected.

Summary

• Entera Bio Ltd. submitted a streamlined Phase 3 protocol, statistical analysis plan (SAP), and open-label extension synopsis to the U.S. Food and Drug Administration (FDA) for EB613 (Oral PTH(1-34), teriparatide).
• FDA feedback on the submission is anticipated within 60 days.
• EB613 is positioned as the first oral anabolic (bone forming) tablet treatment in Phase 3 development for osteoporosis.
• The planned Phase 3 trial will be a multinational, randomized, double-blind, placebo-controlled safety and efficacy study involving 750 postmenopausal women with osteoporosis.
• The primary outcome measure will be the percentage change in total hip Bone Mineral Density (BMD) from baseline to month 12, rather than the previously considered 24 months.
• The required target enrollment for this study is significantly lower than previous assumptions, streamlining trial execution and accelerating the potential path to approval.
• The study is powered to demonstrate increases in total hip BMD comparable with reported outcomes for Forteo at 12 months, which is associated with a 60% to 80% relative reduction in vertebral fracture risk.
• Entera plans to advance the final single tablet formulation of EB613 (Next-Gen EB613) directly into Phase 3, replacing the previous multi-tablet candidate, to avoid future bridging development.
• The Company expects to initiate the Phase 3 study in late 2026, with topline results anticipated in the second half of 2028, approximately one year earlier than previously expected.
• A protocol synopsis for a 12-month open-label extension study was also submitted, expected to run in parallel with the NDA review.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, reflecting significant progress in the clinical development of EB613, with a streamlined trial design, accelerated timeline, and a more patient-friendly formulation, which could significantly enhance its market potential.

Positives

• Submission of a streamlined Phase 3 protocol to the FDA for EB613, marking a pivotal inflection point.
• Primary endpoint for the Phase 3 study changed to 12-month total hip BMD, accelerating the trial timeline by approximately one year.
• Significantly lower target enrollment (750 women) for the Phase 3 study, streamlining trial execution.
• Topline data anticipated in the second half of 2028, approximately one year earlier than previously expected.
• Advancing directly with the final single tablet commercial formulation (Next-Gen EB613) into Phase 3, eliminating the need for future bridging studies.
• FDA alignment and recent regulatory recognition of total hip BMD as an acceptable primary endpoint for fracture.
• EB613 achieved comparable increases in total hip BMD in its 6-month Phase 2 study to those reported for Forteo at 6-months.
• Potential to democratize anabolic treatment for osteoporosis due to its oral, once-daily administration, improving access and ease of use.

Risks

• Changes in the interpretation of clinical data.
• Unfavorable results from clinical trials.
• The FDA's interpretation and review of clinical trial results and analysis.
• Unexpected changes in ongoing and planned preclinical development and clinical trials.
• Delays in the timing of and ability to make regulatory filings and obtain and maintain regulatory approvals for product candidates.
• Potential disruption and delay of manufacturing supply chains.
• Loss of available workforce resources, either by Entera or its collaboration and laboratory partners.
• Impacts to research and development or clinical activities that Entera may be contractually obligated to provide.
• Overall regulatory timelines.
• Uncertainty regarding the size and growth of the potential markets for product candidates.
• Challenges related to the scope, progress, and costs of developing Entera's product candidates.
• Reliance on third parties to conduct clinical trials.
• Operating as a development stage company with limited operating history.
• Competitive position with respect to other products on the market or in development for various disease categories.
• Ability to continue as a going concern absent access to sources of liquidity.
• Ability to comply with Nasdaq's minimum listing standards and other requirements of being a public company.
• Challenges related to Entera's intellectual property position and its ability to protect its intellectual property.

Future Outlook

Entera Bio expects to receive FDA feedback on its streamlined Phase 3 protocol within 60 days. The company plans to initiate the Phase 3 study for EB613 in late 2026, with topline results anticipated in the second half of 2028, approximately one year earlier than previously expected. An open-label extension study is also planned to run in parallel with the potential NDA review, aiming to support the approval and commercialization of EB613 as a simplified, once-daily oral anabolic therapy for osteoporosis.

Management Comments

• "This submission marks a pivotal inflection point for Entera and potentially enables us to get EB613 to patients faster." Miranda Toledano, Chief Executive Officer of Entera.
• "Our goal with EB613 is to democratize anabolic treatment and enable millions of women and men to protect their bones earlier and potentially deter the catastrophic consequences of fracture." Miranda Toledano, Chief Executive Officer of Entera.
• "In a silent and asymptomatic disease, access and ease of administration matters." Miranda Toledano, Chief Executive Officer of Entera.

Industry Context

StockSavvy.ai notes that osteoporosis is a significant and growing public health concern, responsible for over 2 million fractures annually in the US, with projected medical costs rising from $57 billion in 2018 to $95 billion by 2040. Current anabolic therapies, while effective, are administered via subcutaneous injection, leading to underutilization among eligible patients. EB613, as the first oral anabolic tablet in Phase 3 development, addresses a critical unmet need by offering a more convenient and accessible treatment option. This strategic move, leveraging the established benefit-risk profile of Forteo and FDA alignment on total hip BMD as a primary endpoint, positions Entera Bio to potentially disrupt the osteoporosis treatment landscape by expanding the reach of anabolic therapy.

Comparison to Industry Standards

• EB613 is being developed as the first oral, once-daily anabolic tablet treatment for osteoporosis, contrasting with all currently available anabolic therapies (e.g., Forteo) which are administered by subcutaneous (SC) injection.
• The planned Phase 3 trial is powered to demonstrate increases in total hip BMD comparable with reported outcomes for Forteo (teriparatide SC injection, Eli Lilly) at 12 months.
• EB613 achieved comparable increases in total hip BMD in its placebo-controlled 6-month Phase 2 study to those reported for Forteo at the 6-month time point.
• The 505(b)(2) submission for EB613 relies on the well-established benefit-risk profile of Forteo, which has been in clinical use for over 20 years.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to accelerated development timeline, reduced trial costs, and enhanced market potential of a convenient oral therapy.
• Patients (Postmenopausal Women with Osteoporosis): Potential for a more accessible and convenient oral anabolic treatment option, improving adherence and potentially reducing fracture risk earlier.
• Healthcare Providers: A new oral anabolic option could simplify treatment regimens and expand the patient population receiving anabolic therapy, potentially leading to better patient outcomes.

Next Steps

• Receive FDA feedback on the Phase 3 protocol within 60 days.
• Initiate the Phase 3 study in late 2026.
• Anticipate topline results from the Phase 3 study in the second half of 2028.
• Run a 12-month open-label extension study in parallel with the NDA review.
• Submit the 12-month Phase 3 study data and scientific bridge to Forteo in support of the NDA.
• Pursue regulatory approval and commercialization of the single tablet formulation of EB613.

Key Dates

Recommendation

The submission of a streamlined Phase 3 protocol for EB613, coupled with an accelerated timeline for topline data and the adoption of a final commercial single-tablet formulation, represents a significant de-risking event and a clear path towards potential market entry. The oral delivery method addresses a major unmet need in osteoporosis treatment, offering a substantial competitive advantage over existing injectable anabolic therapies. This strategic advancement positions Entera Bio for strong future growth and market penetration, making it a compelling investment opportunity.

Keywords

Osteoporosis, EB613, Oral PTH(1-34), Teriparatide, FDA, Phase 3, Clinical Trial, Bone Mineral Density, BMD, Anabolic, Postmenopausal, Drug Development, Entera Bio, ENTX